ACAD
ACADIA Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.81B
P/E Ratio
9.70
EPS
$2.30
Beta
0.83
52W High
$28.35
52W Low
$13.40
50-Day MA
$23.02
200-Day MA
$23.73
Dividend Yield
—
Profit Margin
36.50%
Forward P/E
51.02
PEG Ratio
50.86
About ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $1.07B |
| Gross Profit (TTM) | $653.71M |
| EBITDA | $116.57M |
| Operating Margin | 6.12% |
| Return on Equity | 39.90% |
| Return on Assets | 4.76% |
| Revenue/Share (TTM) | $6.37 |
| Book Value | $7.21 |
| Price-to-Book | 3.08 |
| Price-to-Sales (TTM) | 3.55 |
| EV/Revenue | 2.816 |
| EV/EBITDA | 25.89 |
| Quarterly Earnings Growth (YoY) | 86.20% |
| Quarterly Revenue Growth (YoY) | 9.40% |
| Shares Outstanding | $170.50M |
| Float | $126.61M |
| % Insiders | 0.57% |
| % Institutions | 99.57% |
Analyst Ratings
Consensus ($31.85 target)
4
Strong Buy12
Buy4
Hold1
SellData last updated: 4/7/2026